출판 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2023년06월
오토인젝터 (Autoinjector) 시장 : 사용법 (재사용 가능, 일회용), 기술 (수동, 자동), 치료법 (류마티스 관절염, 당뇨병, 아나필락시스), 투여 경로 (SC, IM), 용량 (<3ml,> 3ml), 최종 사용자 (재택 의료 , 병원) – 2028년까지 세계 예측
Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) – Global Forecast to 2028
페이지수 | 312 |
도표수 | 480 |
구성 | 영문조사보고서 |
가격 |
The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%.
The key factors driving the growth of the autoinjectors market are the increasing availability of generic versions of autoinjectors and advantages offered by autoinjectors in emergency medical care is expected to propel the growth of the market. However, alternative modes of drug delivery such as oral, nasal, and topical among others are expected to restrain market growth to a certain extent.
The autoinjectors market has been segmented based on technology, usage, route of administration, volume, therapy area, end user and region.
“By technology, the manual autoinjectors segment accounted for the largest share of the autoinjectors market”
Based on technology, the autoinjectors market is categorized into manual, and automatic. The manual autoinjectors segment dominated the market in 2022, owing to the advantages that they offer. These include greater patient control, ease of use, improved safety and accuracy among others. Manual autoinjectors allow patinets and caregivers to administer the medication only when they are ready. This allows for more safe and accurate administration of medication dose.
“By end user, the home care settings segment accounted for the largest share in the autoinjectors market”
Based on end user, the autoinjectors market is segmented into home care settings, hospitals and clinics, and ambulatory care settings. In 2022, the home care settings segment accounted for a largest share of the autoinjectors market. Growth in this market segment can be attributed to relatively lower costs incurred for home care therapies than for treatments in hospitals and the ease of self-administration of drugs using autoinjectors.
“North America: the largest share of the autoinjectors market”
North America accounted for the largest share of the autoinjectors market. The large share of the North America region can be attributed to high awareness and adoption of self-administration of medication. Moreover, favorable reimbursements for autoinjectors has contributed to the growth of the market. Developed countries like the US and Canada have been observed to havehigher awareness and thus, adoption of self-administration drug delivery. This is supported by the favorable reimbursements offered by the government, insurance entities among others in the region.
“Asia Pacific: The fastest-growing region in the autoinjectors market.”
The Asia Pacific autoinjectors market is projected to grow at the highest CAGR during the forecast period. This is attributed to the continuously growing pharmaceutical and biopharmaceutical industries offering generic versions of autoinjectors and growing number of approvals for autoinjector products in the region. Besides, the region has presence of large number of geratric population and a high prevalence of chronic disease including diabetes and cardiovascular diseases. Therefore, the adoption of self-administration of medication is expected to increasing owing to the high frequency of these medications.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, Directors- 30%, and Executives – 25%
• By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America- 10%, and Middle East & Africa- 5%
Prominent Players
• Becton, Dickinson and Company (BD) (US)
• Ypsomed Holding AG (Switzerland)
• sSHL Medical (Switzerland)
• West Pharmaceutical Services, Inc. (US)
• Recipharm AB (Sweden)
• Haselmeier GmbH (Germany)
• Owen Mumford Ltd. (UK)
• Gerresheimer AG (Germany)
• Phillips-Medisize, LLC (US)
• Oval Medical Technologies Ltd. (UK)
• Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China)
• Elcam Drug Delivery Devices (E3D) (Israel)
• Crossject (France)
• Johnson MedTech, LLC. (US), Antares Pharma, Inc. (US)
• Jabil, Inc. (US)
• Congruence Medical Solutions LLC (US)
• AbbVie Inc. (US)
• Amgen Inc. (US)
• Eli Lilly and Company (US)
• Novartis AG (Switzerland)
• Merck KGaA (Germany)
• Viatris Inc. (US)
• Biogen (US)
Research Coverage:
This report provides a detailed picture of the autoinjectors market. It aims at estimating the size and future growth potential of the market across different segments, such as the usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autoinjectors market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers
• Analysis of key drivers (the benefits of autoinjectors in emergency medical care, growth in the number of regulatory approvals, availability of generic versions of autoinjectors, government support and favorable reimbursements, and the growing adoption of self-administration), restraints (alternative drug delivery modes and needle phobia), opportunities (patent expiry of biologics and the increasing shift of therapy to home settings), and challenges (development of autoinjectors for multiple drug viscosities) influencing the growth of the autoinjectors market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the autoinjectors market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical among others in the autoinjectors devices market.
목차
1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.2.1 INCLUSIONS AND EXCLUSIONS 49
1.3 MARKET SCOPE 50
FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION 50
1.3.1 YEARS CONSIDERED 50
1.4 CURRENCY CONSIDERED 51
1.5 LIMITATIONS 51
1.6 STAKEHOLDERS 51
1.7 SUMMARY OF CHANGES 52
1.7.1 RECESSION IMPACT 53
2 RESEARCH METHODOLOGY 54
2.1 RESEARCH DATA 54
FIGURE 2 RESEARCH DESIGN 54
2.1.1 SECONDARY DATA 55
2.1.2 PRIMARY DATA 55
FIGURE 3 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES 56
2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES 57
FIGURE 4 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES 57
FIGURE 5 AUTOINJECTORS MARKET SIZE ESTIMATION: OVERALL APPROACH 57
FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS) 58
2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS 59
FIGURE 7 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 59
FIGURE 8 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS) 60
2.3.1 INSIGHTS FROM PRIMARIES 61
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 61
FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 62
2.4 GROWTH FORECAST 63
FIGURE 11 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS 63
FIGURE 12 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS 64
FIGURE 13 AUTOINJECTORS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 65
FIGURE 14 DATA TRIANGULATION METHODOLOGY 65
2.6 RESEARCH ASSUMPTIONS 66
2.7 RISK ANALYSIS 66
2.8 IMPACT OF RECESSION ON AUTOINJECTORS MARKET 66
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 66
3 EXECUTIVE SUMMARY 68
FIGURE 15 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION) 68
FIGURE 16 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION) 69
FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) 69
FIGURE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION) 70
FIGURE 19 AUTOINJECTOR DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 70
FIGURE 20 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 71
FIGURE 21 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR DEVICES MARKET 72
FIGURE 22 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET 72
4 PREMIUM INSIGHTS 74
4.1 AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW 74
FIGURE 23 INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH 74
4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SHARE, BY USAGE AND COUNTRY (2022) 75
FIGURE 24 DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR DEVICES MARKET IN 2022 75
4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022) 75
FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 2022 75
4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION) 76
FIGURE 26 RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 2028 76
4.5 OVERALL AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2022 76
FIGURE 27 MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 76
4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 77
FIGURE 28 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR DEVICES MARKET FROM 2023 TO 2028 77
4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 78
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 2028 78
5 MARKET OVERVIEW 79
5.1 INTRODUCTION 79
5.2 MARKET DYNAMICS 79
FIGURE 30 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 79
TABLE 2 AUTOINJECTORS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80
5.2.1 DRIVERS 80
5.2.1.1 Benefits of autoinjectors in emergency medical care 80
5.2.1.2 Increasing regulatory approvals for autoinjectors 81
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE 81
5.2.1.3 Availability of generics and biosimilars in autoinjectors 82
5.2.1.4 Government support and favorable reimbursements 82
5.2.1.5 Growing awareness and adoption of self-administration 82
5.2.2 RESTRAINTS 83
5.2.2.1 Alternative drug delivery modes and needle phobia 83
5.2.3 OPPORTUNITIES 83
5.2.3.1 Patent expiry of biologics 83
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS 84
5.2.3.2 Increasing shift of therapy to home settings 84
5.2.4 CHALLENGES 85
5.2.4.1 Development of autoinjectors for multiple drug viscosities 85
5.3 KEY INDUSTRY TRENDS 85
5.3.1 INCREASING ADOPTION OF WEARABLE AUTOINJECTORS 85
5.3.2 DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS 86
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 86
FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS 86
5.5 PRICING ANALYSIS 87
TABLE 5 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020 87
TABLE 6 INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS 87
5.6 VALUE CHAIN ANALYSIS 88
FIGURE 32 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS 88
5.7 SUPPLY CHAIN ANALYSIS 90
FIGURE 33 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS 90
TABLE 7 OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS 91
5.8 ECOSYSTEM ANALYSIS 92
FIGURE 34 ECOSYSTEM ANALYSIS: AUTOINJECTORS MARKET 92
5.9 TECHNOLOGY ANALYSIS 92
5.10 PATENT ANALYSIS 93
FIGURE 35 PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012–APRIL 2023 93
TABLE 8 INDICATIVE LIST OF PATENTS IN AUTOINJECTORS MARKET 94
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 95
TABLE 9 AUTOINJECTORS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 95
5.12 TRADE DATA 96
TABLE 10 IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 2022 96
5.13 REGULATORY ANALYSIS 97
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
5.14 PORTER’S FIVE FORCES ANALYSIS 101
TABLE 15 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 101
5.14.1 THREAT OF NEW ENTRANTS 101
5.14.2 THREAT OF SUBSTITUTES 101
5.14.3 BARGAINING POWER OF SUPPLIERS 101
5.14.4 BARGAINING POWER OF BUYERS 101
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 101
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 102
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES 102
5.15.2 BUYING CRITERIA FOR AUTOINJECTOR DEVICES 102
FIGURE 37 KEY BUYING CRITERIA FOR END USERS 102
6 AUTOINJECTORS MARKET, BY USAGE 103
6.1 INTRODUCTION 104
TABLE 16 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 104
TABLE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (MILLION UNITS) 104
TABLE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 104
6.2 DISPOSABLE AUTOINJECTORS 105
6.2.1 CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH 105
TABLE 19 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 20 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 105
TABLE 21 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 22 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 23 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 24 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 25 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 26 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 27 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.3 REUSABLE AUTOINJECTORS 108
6.3.1 REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET 108
TABLE 28 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 29 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 109
TABLE 30 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 31 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 32 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 33 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 34 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 35 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 36 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
7 AUTOINJECTORS MARKET, BY TECHNOLOGY 113
7.1 INTRODUCTION 114
TABLE 37 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 38 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (MILLION UNITS) 114
TABLE 39 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
7.2 MANUAL AUTOINJECTORS 115
7.2.1 MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD 115
TABLE 40 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 41 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 116
TABLE 42 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 43 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 44 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 45 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 46 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 47 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 48 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
7.3 AUTOMATIC AUTOINJECTORS 118
7.3.1 AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS 118
TABLE 49 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 50 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 120
TABLE 51 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 52 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 53 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 54 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 55 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 56 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 57 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION 123
8.1 INTRODUCTION 124
TABLE 58 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 124
TABLE 59 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (MILLION UNITS) 124
8.2 SUBCUTANEOUS 124
8.2.1 INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH 124
TABLE 60 AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 61 SUBCUTANEOUS AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 125
TABLE 62 NORTH AMERICA: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 63 EUROPE: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 64 ASIA PACIFIC: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 126
8.3 INTRAMUSCULAR 127
8.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION 127
TABLE 65 AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 66 INTRAMUSCULAR AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 128
TABLE 67 NORTH AMERICA: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 68 EUROPE: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 69 ASIA PACIFIC: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 129
9 AUTOINJECTORS MARKET, BY THERAPY AREA 130
9.1 INTRODUCTION 131
TABLE 70 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 131
TABLE 71 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (MILLION UNITS) 131
TABLE 72 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 132
9.2 RHEUMATOID ARTHRITIS 132
9.2.1 BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH 132
TABLE 73 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 74 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (MILLION UNITS) 133
TABLE 75 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 76 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 77 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 78 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 79 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 80 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 81 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION) 136
9.3 DIABETES 136
9.3.1 LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS 136
FIGURE 38 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS), 2019 VS. 2030 VS. 2045 137
TABLE 82 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 83 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (MILLION UNITS) 138
TABLE 84 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 85 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 86 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 87 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 88 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 89 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 90 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION) 140
9.4 MULTIPLE SCLEROSIS 140
9.4.1 AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH 140
TABLE 91 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 92 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (MILLION UNITS) 141
TABLE 93 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 94 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 95 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 96 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 97 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 98 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 99 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION) 144
9.4.2 ANAPHYLAXIS 144
9.4.2.1 Increasing prevalence of food allergies to drive growth 144
TABLE 100 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION) 145
TABLE 101 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (MILLION UNITS) 145
TABLE 102 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 103 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 104 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 105 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 106 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 107 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 108 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION) 148
9.4.3 OTHER THERAPY AREAS 148
TABLE 109 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION) 149
TABLE 110 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (MILLION UNITS) 149
TABLE 111 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 112 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 113 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 114 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION) 151
TABLE 115 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 116 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 117 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 152
10 AUTOINJECTORS MARKET, BY VOLUME 153
10.1 INTRODUCTION 154
TABLE 118 AUTOINJECTORS MARKET, BY VOLUME, 2021–2028 (USD MILLION) 154
TABLE 119 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (MILLION UNITS) 154
10.2 UP TO 3 ML VOLUME 154
10.2.1 INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH 154
TABLE 120 UP TO 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 121 UP TO 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 155
10.3 ABOVE 3 ML VOLUME (LARGE VOLUME) 156
10.3.1 GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH 156
TABLE 122 ABOVE 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION) 156
TABLE 123 ABOVE 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS) 156
11 AUTOINJECTORS MARKET, BY END USER 157
11.1 INTRODUCTION 158
TABLE 124 AUTOINJECTORS MARKET, BY END USER, 2021–2028 (USD MILLION) 158
11.2 HOME CARE SETTINGS 158
11.2.1 COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH 158
TABLE 125 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION) 159
TABLE 126 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 127 EUROPE: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 128 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 160
11.3 HOSPITALS AND CLINICS 161
11.3.1 USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH 161
TABLE 129 AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 130 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 131 EUROPE: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 132 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 162
11.4 AMBULATORY CARE SETTINGS 163
11.4.1 INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH 163
TABLE 133 AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 134 NORTH AMERICA: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 135 EUROPE: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 136 ASIA PACIFIC: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 164
12 AUTOINJECTORS MARKET, BY REGION 165
12.1 INTRODUCTION 166
TABLE 137 AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 138 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 166
12.2 NORTH AMERICA 167
FIGURE 39 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT 167
TABLE 139 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 140 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 168
TABLE 141 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 168
TABLE 142 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 169
TABLE 143 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 169
TABLE 144 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION) 169
TABLE 145 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 170
TABLE 146 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 147 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 170
TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 171
TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 171
TABLE 150 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 171
TABLE 151 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION) 172
TABLE 152 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 172
12.2.1 US 172
12.2.1.1 US to dominate North American market during forecast period 172
TABLE 153 AUTOINJECTORS APPROVED BY US FDA, 2022 174
TABLE 154 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 174
TABLE 155 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 174
TABLE 156 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 175
TABLE 157 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 175
TABLE 158 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 175
TABLE 159 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 176
TABLE 160 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 176
TABLE 161 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 176
TABLE 162 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 177
TABLE 163 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 177
12.2.2 CANADA 177
12.2.2.1 Rising prevalence of chronic diseases to drive growth 177
TABLE 164 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 178
TABLE 165 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178
TABLE 166 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 178
TABLE 167 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 179
TABLE 168 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 179
TABLE 169 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 179
TABLE 170 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180
TABLE 171 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 180
TABLE 172 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 180
TABLE 173 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 181
12.2.3 NORTH AMERICA: RECESSION IMPACT 181
12.3 EUROPE 182
TABLE 174 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 175 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 182
TABLE 176 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 182
TABLE 177 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 183
TABLE 178 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 183
TABLE 179 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION) 183
TABLE 180 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 184
TABLE 181 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 182 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 184
TABLE 183 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 185
TABLE 184 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 185
TABLE 185 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 185
TABLE 186 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION) 186
TABLE 187 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 186
12.3.1 GERMANY 186
12.3.1.1 Growing government support to propel market 186
TABLE 188 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 187
TABLE 189 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 187
TABLE 190 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 187
TABLE 191 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 188
TABLE 192 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 188
TABLE 193 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 188
TABLE 194 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 189
TABLE 195 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 189
TABLE 196 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 189
TABLE 197 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 190
12.3.2 UK 190
12.3.2.1 High prevalence of allergic conditions to boost growth 190
TABLE 198 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 190
TABLE 199 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191
TABLE 200 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 191
TABLE 201 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 191
TABLE 202 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 192
TABLE 203 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 192
TABLE 204 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 192
TABLE 205 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 193
TABLE 206 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 193
TABLE 207 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 193
12.3.3 FRANCE 194
12.3.3.1 Increasing prevalence of chronic diseases to support growth 194
TABLE 208 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 194
TABLE 209 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194
TABLE 210 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 194
TABLE 211 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 195
TABLE 212 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 195
TABLE 213 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 195
TABLE 214 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 196
TABLE 215 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 196
TABLE 216 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 196
TABLE 217 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 197
12.3.4 ITALY 197
12.3.4.1 Rising prevalence of chronic diseases to propel growth 197
TABLE 218 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 197
TABLE 219 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 198
TABLE 220 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 198
TABLE 221 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 198
TABLE 222 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 199
TABLE 223 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 199
TABLE 224 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 199
TABLE 225 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 200
TABLE 226 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 200
TABLE 227 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 200
12.3.5 SPAIN 201
12.3.5.1 Favorable reimbursement scenario to support growth 201
TABLE 228 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 201
TABLE 229 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 201
TABLE 230 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 202
TABLE 231 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 202
TABLE 232 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 202
TABLE 233 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 203
TABLE 234 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 203
TABLE 235 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 203
TABLE 236 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 204
TABLE 237 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 204
12.3.6 REST OF EUROPE 204
TABLE 238 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 205
TABLE 239 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 205
TABLE 240 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 205
TABLE 241 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 206
TABLE 242 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 206
TABLE 243 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 206
TABLE 244 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 207
TABLE 245 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 207
TABLE 246 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 207
TABLE 247 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 208
12.3.7 EUROPE: RECESSION IMPACT 208
12.4 ASIA PACIFIC 208
FIGURE 40 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET SNAPSHOT 209
TABLE 248 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 210
TABLE 249 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 210
TABLE 250 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 210
TABLE 251 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 211
TABLE 252 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 211
TABLE 253 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION) 211
TABLE 254 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 212
TABLE 255 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 212
TABLE 256 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 212
TABLE 257 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 213
TABLE 258 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 213
TABLE 259 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 213
TABLE 260 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION) 214
TABLE 261 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 214
12.4.1 JAPAN 214
12.4.1.1 Presence of large geriatric population to boost growth 214
TABLE 262 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 215
TABLE 263 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 215
TABLE 264 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 215
TABLE 265 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 216
TABLE 266 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 216
TABLE 267 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 216
TABLE 268 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 217
TABLE 269 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 217
TABLE 270 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 217
TABLE 271 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 218
12.4.2 CHINA 218
12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to drive growth 218
TABLE 272 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 219
TABLE 273 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 219
TABLE 274 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 219
TABLE 275 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 220
TABLE 276 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 220
TABLE 277 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 220
TABLE 278 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 221
TABLE 279 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 221
TABLE 280 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 221
TABLE 281 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 222
12.4.3 INDIA 222
12.4.3.1 Increasing burden of diabetes and CVD to drive growth 222
TABLE 282 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 222
TABLE 283 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 223
TABLE 284 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 223
TABLE 285 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 223
TABLE 286 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 224
TABLE 287 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 224
TABLE 288 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 224
TABLE 289 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 225
TABLE 290 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 225
TABLE 291 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 225
12.4.4 SOUTH KOREA 226
12.4.4.1 Regulatory approvals for autoinjectors to drive growth 226
TABLE 292 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 226
TABLE 293 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 226
TABLE 294 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 227
TABLE 295 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 227
TABLE 296 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 227
TABLE 297 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 228
TABLE 298 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 228
TABLE 299 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 228
TABLE 300 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 229
TABLE 301 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 229
12.4.5 REST OF ASIA PACIFIC 229
TABLE 302 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 230
TABLE 303 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 230
TABLE 304 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 230
TABLE 305 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 231
TABLE 306 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 231
TABLE 307 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 231
TABLE 308 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 232
TABLE 309 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 232
TABLE 310 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 232
TABLE 311 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 233
12.4.6 ASIA PACIFIC: RECESSION IMPACT 233
12.5 LATIN AMERICA 233
12.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH 233
TABLE 312 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 234
TABLE 313 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 234
TABLE 314 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 234
TABLE 315 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 235
TABLE 316 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION) 235
TABLE 317 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 235
TABLE 318 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 236
TABLE 319 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 236
TABLE 320 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 236
TABLE 321 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 237
TABLE 322 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION) 237
TABLE 323 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 237
12.5.2 LATIN AMERICA: RECESSION IMPACT 238
12.6 MIDDLE EAST & AFRICA 238
12.6.1 FAVORABLE REFORMS IN AFRICA AND MIDDLE EASTERN COUNTRIES TO DRIVE GROWTH 238
TABLE 324 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION) 239
TABLE 325 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 239
TABLE 326 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 239
TABLE 327 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 240
TABLE 328 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION) 240
TABLE 329 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 240
TABLE 330 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION) 241
TABLE 331 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 241
TABLE 332 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 241
TABLE 333 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION) 242
TABLE 334 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION) 242
TABLE 335 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION) 242
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 243
13 COMPETITIVE LANDSCAPE 244
13.1 INTRODUCTION 244
13.2 STRATEGIES ADOPTED BY KEY PLAYERS 244
FIGURE 41 AUTOINJECTOR DEVICES AND FINISHED FORMULATIONS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 245
13.3 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET 246
FIGURE 42 AUTOINJECTOR DEVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 246
13.4 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET 246
FIGURE 43 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 247
13.5 MARKET SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET 247
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET, 2022 247
TABLE 336 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION 248
13.6 MARKET SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET 249
FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET, 2022 249
TABLE 337 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION 249
13.7 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 250
FIGURE 46 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 251
13.7.1 STARS 252
13.7.2 EMERGING LEADERS 252
13.7.3 PERVASIVE PLAYERS 252
13.7.4 PARTICIPANTS 252
13.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 252
13.8.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 252
TABLE 338 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET 252
13.8.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 253
TABLE 339 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET 253
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES 255
FIGURE 47 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 255
13.9.1 PROGRESSIVE COMPANIES 256
13.9.2 STARTING BLOCKS 256
13.9.3 RESPONSIVE COMPANIES 256
13.9.4 DYNAMIC COMPANIES 256
13.10 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 256
TABLE 340 AUTOINJECTORS MARKET: LIST OF KEY STARTUP/SME PLAYERS 256
TABLE 341 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 257
13.11 COMPETITIVE SCENARIO AND TRENDS 257
13.11.1 PRODUCT LAUNCHES 257
TABLE 342 AUTOINJECTORS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023 257
13.11.2 DEALS 257
TABLE 343 AUTOINJECTORS MARKET: DEALS, JANUARY 2020–APRIL 2023 258
13.11.3 OTHER DEVELOPMENTS 259
TABLE 344 AUTOINJECTORS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023 259
13.11.4 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS 260
TABLE 345 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS 260
13.11.5 DEVICES FOR LARGE-VOLUME FORMULATIONS 260
TABLE 346 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS 260
13.11.6 DEVICES FOR HIGHLY VISCOUS FORMULATIONS 261
TABLE 347 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS 261
TABLE 348 FORMULATIONS AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS 262
13.11.7 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET 263
14 COMPANY PROFILES 264
14.1 KEY PLAYERS: DEVICES 264
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 BECTON, DICKINSON AND COMPANY (BD) 264
TABLE 349 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 264
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 265
TABLE 350 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS 265
TABLE 351 BECTON, DICKINSON AND COMPANY: DEALS 266
TABLE 352 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS 266
14.1.2 YPSOMED HOLDING AG 267
TABLE 353 YPSOMED HOLDING AG: COMPANY OVERVIEW 267
FIGURE 49 YPSOMED HOLDING AG: COMPANY SNAPSHOT 268
TABLE 354 YPSOMED HOLDING AG: PRODUCT OFFERINGS 268
TABLE 355 YPSOMED HOLDING AG: PRODUCT LAUNCHES 269
TABLE 356 YPSOMED HOLDING AG: DEALS 269
14.1.3 SHL MEDICAL 271
TABLE 357 SHL MEDICAL: COMPANY OVERVIEW 271
TABLE 358 SHL MEDICAL: PRODUCT OFFERINGS 271
TABLE 359 SHL MEDICAL: DEALS 272
TABLE 360 SHL MEDICAL: OTHER DEVELOPMENTS 273
14.1.4 WEST PHARMACEUTICAL SERVICES, INC. 274
TABLE 361 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 274
FIGURE 50 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022) 275
TABLE 362 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT OFFERINGS 275
TABLE 363 WEST PHARMACEUTICAL SERVICES, INC.: OTHER DEVELOPMENTS 276
14.1.5 RECIPHARM AB 277
TABLE 364 RECIPHARM AB: COMPANY OVERVIEW 277
TABLE 365 RECIPHARM AB: PRODUCT OFFERINGS 277
TABLE 366 RECIPHARM AB: DEALS 278
14.1.6 HASELMEIER GMBH 279
TABLE 367 HASELMEIER GMBH: COMPANY OVERVIEW 279
TABLE 368 HASELMEIER GMBH: PRODUCT OFFERINGS 279
TABLE 369 HASELMEIER GMBH: DEALS 280
TABLE 370 HASELMEIER GMBH: PRODUCT LAUNCHES 280
14.1.7 OWEN MUMFORD LTD. 281
TABLE 371 OWEN MUMFORD LTD.: COMPANY OVERVIEW 281
TABLE 372 OWEN MUMFORD LTD.: PRODUCT OFFERINGS 281
TABLE 373 OWEN MUMFORD LTD.: PRODUCT LAUNCHES 282
TABLE 374 OWEN MUMFORD LTD.: DEALS 282
TABLE 375 OWEN MUMFORD LTD.: OTHER DEVELOPMENTS 282
14.1.8 GERRESHEIMER AG 283
TABLE 376 GERRESHEIMER AG: COMPANY OVERVIEW 283
FIGURE 51 GERRESHEIMER AG: COMPANY SNAPSHOT (2022) 284
TABLE 377 GERRESHEIMER AG: PRODUCT OFFERINGS 284
TABLE 378 GERRESHEIMER AG: DEALS 285
14.1.9 PHILLIPS-MEDISIZE, LLC 286
TABLE 379 PHILIPS-MEDISIZE, LLC: COMPANY OVERVIEW 286
TABLE 380 PHILIPS MEDISIZE, LLC: PRODUCT OFFERINGS 286
TABLE 381 PHILIPS MEDISIZE, LLC: PRODUCT LAUNCHES 287
TABLE 382 PHILIPS-MEDISIZE, LLC: OTHER DEVELOPMENTS 287
14.1.10 OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.) 288
TABLE 383 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW 288
TABLE 384 OVAL MEDICAL TECHNOLOGIES LTD.: PRODUCT OFFERINGS 288
14.1.11 KALEO, INC. 289
TABLE 385 KALEO, INC.: COMPANY OVERVIEW 289
TABLE 386 KALEO, INC.: PRODUCT OFFERINGS 289
14.1.12 SOLTEAM INCORPORATION CO., LTD. 290
TABLE 387 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW 290
TABLE 388 SOLTEAM INCORPORATION CO., LTD.: PRODUCT OFFERINGS 290
14.1.13 ELCAM DRUG DELIVERY DEVICES (E3D) 291
14.1.14 CROSSJECT 293
TABLE 391 CROSSJECT: COMPANY OVERVIEW 293
TABLE 392 CROSSJECT: PRODUCT OFFERINGS 293
14.1.15 JOHNSON MEDTECH, LLC. (PART OF JOHNSON ELECTRIC HOLDINGS LTD.) 294
TABLE 393 JOHNSON MEDTECH, LLC.: COMPANY OVERVIEW 294
TABLE 394 JOHNSON MEDTECH, LLC: PRODUCT OFFERINGS 294
14.1.16 ANTARES PHARMA, INC. (PART OF HALOZYME, INC.) 295
TABLE 395 ANTARES PHARMA, INC.: COMPANY OVERVIEW 295
FIGURE 52 ANTARES PHARMA, INC.: COMPANY SNAPSHOT 296
TABLE 396 ANTARES PHARMA, INC.: PRODUCT OFFERINGS 297
TABLE 397 ANTARES PHARMA, INC.: DEALS 297
14.1.17 JABIL, INC. 298
TABLE 398 JABIL, INC.: COMPANY OVERVIEW 298
TABLE 399 JABIL INC.: PRODUCT OFFERINGS 298
14.1.18 CONGRUENCE MEDICAL SOLUTIONS LLC 299
TABLE 400 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW 299
TABLE 401 CONGRUENCE MEDICAL SOLUTIONS LLC: PRODUCT OFFERINGS 299
14.2 KEY PLAYERS: FINISHED FORMULATIONS 300
14.2.1 ABBVIE INC. 300
TABLE 402 ABBVIE INC.: COMPANY OVERVIEW 300
FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT 301
TABLE 403 ABBVIE INC.: PRODUCT OFFERINGS 302
TABLE 404 ABBVIE INC.: PRODUCT LAUNCHES 302
TABLE 405 ABBVIE INC.: OTHER DEVELOPMENTS 303
14.2.2 AMGEN INC. 304
TABLE 406 AMGEN INC.: COMPANY OVERVIEW 304
FIGURE 54 AMGEN INC.: COMPANY SNAPSHOT 305
TABLE 407 AMGEN INC.: PRODUCT OFFERINGS 306
TABLE 408 AMGEN INC.: PRODUCT LAUNCHES 306
14.2.3 ELI LILLY AND COMPANY 307
TABLE 409 ELI LILY AND COMPANY: COMPANY OVERVIEW 307
FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 308
TABLE 410 ELI LILY AND COMPANY: PRODUCT OFFERINGS 308
TABLE 411 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS 309
14.2.4 NOVARTIS AG 310
TABLE 412 NOVARTIS AG: COMPANY OVERVIEW 310
FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT 311
TABLE 413 NOVARTIS AG: PRODUCT OFFERINGS 311
TABLE 414 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS 312
14.2.5 MERCK KGAA 313
TABLE 415 MERCK KGAA: COMPANY OVERVIEW 313
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT 314
TABLE 416 MERCK KGAA: PRODUCT OFFERINGS 314
14.2.6 VIATRIS INC. (FORMERLY MYLAN INC.) 315
TABLE 417 VIATRIS INC.: COMPANY OVERVIEW 315
FIGURE 58 VIATRIS INC.: COMPANY SNAPSHOT 315
TABLE 418 VIATRIS INC.: PRODUCT OFFERINGS 316
14.2.7 BIOGEN 317
TABLE 419 BIOGEN: COMPANY OVERVIEW 317
FIGURE 59 BIOGEN: COMPANY SNAPSHOT 318
TABLE 420 BIOGEN: PRODUCT OFFERINGS 318
TABLE 421 BIOGEN: OTHER DEVELOPMENTS 319
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 320
15.1 DISCUSSION GUIDE 320
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 324
15.3 CUSTOMIZATION OPTIONS 326
15.4 RELATED REPORTS 327
15.5 AUTHOR DETAILS 328